Comment on FDA draft guidance for industry FDA-2019-D-0934: Adjusting for covariates in randomized clinical trials for drugs and biological products

Abstract

This is a unsolicited commentary on the FDA draft guidance on covariate adjustment.

comments powered by Disqus